The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
Both standard and high doses of a diabetes drug protect kidneys equally well, giving doctors more flexibility in treating patients.
Post-hoc analysis of 4,330 CANVAS trial participants found that both canagliflozin 100mg and 300mg doses provided equivalent and statistically significant renal protection vs placebo (HR 0.49 and 0.41), with no meaningful difference between doses on any renal, CV, or safety outcome. These findings support clinical flexibility in canagliflozin dosing and may reduce dose-escalation anxiety in practice.
What the study was
- Study design
- Post-hoc analysis of RCT (CANVAS trial; participant-level data)
- Population
- T2DM adults with high CV risk from CANVAS trial; 4,330 participants (100mg and 300mg canagliflozin arms + placebo)
- Sample size
- 4330
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Diabetes Obes Metab
Why it surfaced
Post-hoc RCT analysis (n=4,330) clarifying dose equivalence for canagliflozin renal outcomes; directly applicable to prescribing decisions in T2DM with CKD.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.